Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial
Posted inGastroenterology news Oncology

Perioperative Nivolumab Combined with Irreversible Electroporation Shows Antitumoral Effect in High-Risk BCLC A Hepatocellular Carcinoma: Results from the NIVOLEP Phase 2 Trial

The NIVOLEP phase 2 trial demonstrates that perioperative nivolumab (neoadjuvant and adjuvant) combined with irreversible electroporation achieves 70.6% one-year local recurrence-free survival in BCLC A HCC patients with high recurrence risk. Pathological response correlated with immune activation pathways, suggesting synergistic effects between immunotherapy and ablation.
Portal Tryptophan Depletion Drives Hyper-Reactive Neutrophils in Alcoholic Liver Disease: Insights from a Prospective TIPS Study
Posted inGastroenterology news

Portal Tryptophan Depletion Drives Hyper-Reactive Neutrophils in Alcoholic Liver Disease: Insights from a Prospective TIPS Study

A prospective study reveals that decreased tryptophan levels in portal circulation induce neutrophil hyperactivation in alcoholic liver disease. In vitro supplementation with tryptophan ameliorated neutrophil activation, identifying the gut-liver metabolic crosstalk as a potential therapeutic target for mitigating neutrophil-driven liver injury.
Kissing and Celiac Disease: New Evidence That Simple Precautions Effectively Minimize Gluten Transfer Risk
Posted inGastroenterology news

Kissing and Celiac Disease: New Evidence That Simple Precautions Effectively Minimize Gluten Transfer Risk

A prospective study in Gastroenterology examined gluten transfer through kissing in celiac-discordant couples. Researchers found that while low-level gluten is detectable in saliva, the risk of clinically significant transfer is minimal. A simple intervention—drinking 4 oz of water before kissing—effectively eliminates detectable gluten, offering practical guidance for patients managing celiac disease.
New EHR-Based Model PRIME Achieves 0.75 AUC in Predicting Pancreatic Cancer Risk Across 11 Million Patients
Posted inGastroenterology Hematology-Oncology news

New EHR-Based Model PRIME Achieves 0.75 AUC in Predicting Pancreatic Cancer Risk Across 11 Million Patients

Researchers developed PRIME, a parsimonious risk stratification model for pancreatic ductal adenocarcinoma using electronic health record data. Validated across US health systems and the UK Biobank, PRIME retained 19 predictors and achieved strong discrimination, enabling targeted early detection in high-risk populations.
Why Hepatitis E Remains a Silent Threat in Transplant Recipients: Key Insights from Two Decades of Data
Posted inGastroenterology Infectious Diseases news Transplantation

Why Hepatitis E Remains a Silent Threat in Transplant Recipients: Key Insights from Two Decades of Data

A 20-year retrospective study of 6,452 solid organ transplant patients reveals hepatitis E infection rates of 3.5%, with chronicity rates exceeding 65%. The findings highlight the critical importance of HEV screening and the effectiveness of extended ribavirin therapy in achieving viral clearance.
Enterococcus faecalis Drives MHC-II Expression in Intestinal Epithelium: A Novel Mechanism Linking Gut Microbiome Dysbiosis to Lethal Graft-versus-Host Disease
Posted inGastroenterology Hematology-Oncology news

Enterococcus faecalis Drives MHC-II Expression in Intestinal Epithelium: A Novel Mechanism Linking Gut Microbiome Dysbiosis to Lethal Graft-versus-Host Disease

Research reveals that Enterococcus faecalis colonization induces MHC-II expression in intestinal epithelial cells during graft-versus-host disease, with a lantibiotic-producing Blautia producta strain demonstrating potential to restore colonization resistance and improve survival outcomes.
Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy
Posted inCardiology Gastroenterology news

Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy

This study identifies the integrin αV-YAP-CTGF axis in liver sinusoidal endothelial cells as a primary driver of fibrosis and carcinogenesis in congestive hepatopathy. By targeting this mechanosensitive pathway, researchers demonstrated a significant reduction in portal hypertension and liver damage in both murine models and human clinical samples.
From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy
Posted inCardiology Gastroenterology news

From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy

Researchers have identified a novel signaling pathway in liver sinusoidal endothelial cells (LSECs) that drives fibrosis and liver cancer in congestive hepatopathy. The study highlights the Integrin αV-YAP-CTGF axis as a critical mechanism and potential therapeutic target for patients with chronic hepatic congestion.